Literature DB >> 11375345

Increased prevalence of microthromboses in retinal capillaries of diabetic individuals.

D Boeri1, M Maiello, M Lorenzi.   

Abstract

In diabetic retinopathy, capillary nonperfusion and eventual obliteration can lead to retinal ischemia and sight-threatening neovascularization. The occurrence of retinal microthrombosis in human diabetes has long been suspected and occasionally observed but never systematically demonstrated. We used trypsin digestion to isolate the intact vascular network from retinas obtained postmortem from nine diabetic donors (age 64 +/- 11 years, duration of diabetes 6 +/- 4 years; mean +/- SD) and eight age-matched nondiabetic donors. Topographically matched sectors (each one-sixth of retina) of diabetic and nondiabetic retinas were tested sequentially with antibodies to fibrin cross-linking factor XIII and platelet glycoprotein (GP)-IIIa to identify fibrin-platelet thrombi. In some trypsin digests, we also examined vascular cell apoptosis. The retina from a nondiabetic donor, 24 years of age, who had died of trauma, was used to exclude confounding influences caused by the postmortem period. When compared with those of nondiabetic donors, the retinas of diabetic donors showed double the number of capillary segments with colocalized immunostaining for factor XIII and GPIIIa (P = 0.02). The total area of the positive segments was fourfold greater in the diabetic than in the nondiabetic donors (P = 0.02) and correlated with the duration of diabetes (r = 0.71, P < 0.05). Large thrombi were six times more frequent in the diabetic donors (P = 0.03), and there was a significant topographical association of microthrombosis with apoptotic cells in both diabetic and nondiabetic vessels (P = 0.0001). Hence, diabetes of short duration was found to be associated with a greater than normal number and size of platelet-fibrin thrombi in the retinal capillaries. These thrombi can contribute to capillary obliteration and retinal ischemia and may be a practical target for early drug intervention.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11375345     DOI: 10.2337/diabetes.50.6.1432

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  33 in total

1.  Aspirin for diabetic retinopathy.

Authors:  Eva M Kohner
Journal:  BMJ       Date:  2003-11-08

2.  Metabolic memory and diabetic retinopathy: role of inflammatory mediators in retinal pericytes.

Authors:  Renu A Kowluru; Qing Zhong; Mamta Kanwar
Journal:  Exp Eye Res       Date:  2010-02-17       Impact factor: 3.467

Review 3.  Immunological mechanisms in the pathogenesis of diabetic retinopathy.

Authors:  Anthony P Adamis; Adrienne J Berman
Journal:  Semin Immunopathol       Date:  2008-03-14       Impact factor: 9.623

4.  Diabetes-related microvascular and macrovascular diseases in the physical therapy setting.

Authors:  W Todd Cade
Journal:  Phys Ther       Date:  2008-09-18

5.  Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARgamma-independent mechanism.

Authors:  M Artwohl; C Fürnsinn; W Waldhäusl; T Hölzenbein; G Rainer; A Freudenthaler; M Roden; S M Baumgartner-Parzer
Journal:  Diabetologia       Date:  2005-02-24       Impact factor: 10.122

Review 6.  Current knowledge on diabetic retinopathy from human donor tissues.

Authors:  Jessica H Eisma; Jennifer E Dulle; Patrice E Fort
Journal:  World J Diabetes       Date:  2015-03-15

7.  IL-2 and IFN-gamma in the retina of diabetic rats.

Authors:  Siv Johnsen-Soriano; María Sancho-Tello; Emma Arnal; Amparo Navea; Enrique Cervera; Francisco Bosch-Morell; Maria Miranda; Francisco Javier Romero
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-03-06       Impact factor: 3.117

8.  Comparison of three strains of diabetic rats with respect to the rate at which retinopathy and tactile allodynia develop.

Authors:  T S Kern; C M Miller; J Tang; Y Du; S L Ball; L Berti-Matera
Journal:  Mol Vis       Date:  2010-08-15       Impact factor: 2.367

Review 9.  Approaches to prevention of cardiovascular complications and events in diabetes mellitus.

Authors:  Sergio Coccheri
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  Pycnogenol for diabetic retinopathy. A review.

Authors:  F Schönlau; P Rohdewald
Journal:  Int Ophthalmol       Date:  2001       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.